Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PYGL | P06737 | 8/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | MMP7 | P09237 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10442216 | 1.00 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1MMP2CA12CA1 | |
| SCHEMBL3285856 | 0.98 | MMP2 (0.41) | SMN1; SMN2ALDH1A1MMP2CA12CA1 | |
| SCHEMBL6885724 | 0.98 | MMP2 (0.41) | SMN1; SMN2ALDH1A1MMP2CA12CA1 | |
| SCHEMBL329758 | 0.98 | MMP2 (0.41) | SMN1; SMN2ALDH1A1MMP2CA12CA1 | |
| SCHEMBL19083742 | 0.96 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1MMP2CA12CA1 | |
| SCHEMBL19083902 | 0.96 | SMN1; SMN2 (0.37) | SMN1; SMN2ALDH1A1MMP2CA12CA1 | |
| SCHEMBL19083735 | 0.91 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1MMP2KMT2APYGL | |
| SCHEMBL31730569 | 0.91 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1MMP2KMT2APYGL | |
| SCHEMBL13544389 | 0.91 | SMN1; SMN2 (0.39) | SMN1; SMN2ALDH1A1MMP2KMT2APYGL | |
| SCHEMBL21186419 | 0.85 | MMP2 (0.39) | SMN1; SMN2ALDH1A1MMP2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11667645-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667645-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667645-B2 | Granzyme B directed imaging and therapy | CYTOSITE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| EP-3752145-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | Cytosite Biopharma Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2020-11-26 | — | — | US | disclosed |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. | 2020-11-26 | — | — | US | disclosed |
| WO-2019160916-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | CYTOSITE BIOPHARMA INC. (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20120252734-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | OLSON GARY LEE (US) | 2012-10-04 | — | — | US | disclosed |
| US-8222215-B2 | Methods for the use of inhibitors of antigen presentation by MHC class II molecules | PROVID PHARMACEUTICALS, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-20110217324-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF | PROVID PHARMACEUTICALS, INC. | 2011-09-08 | — | — | US | disclosed |
| US-20090111755-A1 | METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | PROVID PHARMACEUTICALS, INC. | 2009-04-30 | — | — | US | disclosed |
| US-7439231-B2 | Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof | PROVID PHARMACEUTICALS, INC. (US) | 2008-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257388-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | SMN1; SMN2 1756/4885ALDH1A1 4592/4885MMP2 276/4885 |
| US-20110217324-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES AND METHODS OF USE THEREOF | HLA-DRB1, CD74, MICA | SMN1; SMN2 3457/4885ALDH1A1 2379/4885MMP2 601/4885 |
| US-20200369673-A1 | GRANZYME B DIRECTED IMAGING AND THERAPY | GZMB, PRF1, CTSB | SMN1; SMN2 1756/4885ALDH1A1 4592/4885MMP2 276/4885 |
| US-20090111755-A1 | METHODS FOR THE USE OF INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | HLA-DRB1, CD74, MICA | SMN1; SMN2 3337/4885ALDH1A1 1863/4885MMP2 673/4885 |
| US-20120252734-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY MHC CLASS II MOLECULES | HLA-DRB1, CD74, MICA | SMN1; SMN2 3602/4885ALDH1A1 2074/4885MMP2 799/4885 |
| US-11667645-B2 | Granzyme B directed imaging and therapy | GZMB, PRF1, CTSB | SMN1; SMN2 1756/4885ALDH1A1 4592/4885MMP2 276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.